The potential effect of statins on rituximab immunotherapy.
Cragg
Mark S
MS
D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D000075202:Contraindications; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069283:Rituximab